BridgeBio Pharma Inc BBIO

Morningstar Rating
$78.30 +0.13 (0.17%)
View Full Chart

Company Report

Price vs Fair Value

BBIO is trading at a LOCK|F>H%v^ premium.
Price
$78.30
Fair Value
<^<
Uncertainty
LOCK|TG D<y<?
1-Star Price
LOCK|$.c#c
5-Star Price
LOCK|.^g
Economic Moat
LOCK|ny&
Capital Allocation
LOCK|?JJR!%

Bulls Say, Bears Say

Bulls

The successful commercialization of Attruby could establish BridgeBio as a key player in the ATTR-CM market, significantly improving its path to profitability.

Bears

BridgeBio has historically faced challenges in developing pipeline candidates and bringing them to market.

News

Articles & Videos

Trading Information

Previous Close Price
$78.17
Day Range
$77.58–79.13
52-Week Range
$62.50–93.42
Bid/Ask
$72.99 / $80.30
Shares Outstanding
194.80M
Market Cap
$15.25B
Volume/Avg
1M / 3M

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
16.15
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
1.79%

Company Profile

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
839

Competitors

Valuation

Metric
BBIO
BNTX
ALNY
Price/Earnings (Normalized)
——8.15
Price/Book Value
—1.066.13
Price/Sales
16.157.624.53
Price/Cash Flow
——16.19
Price/Earnings
BBIO
BNTX
ALNY

Financial Strength

Metric
BBIO
BNTX
ALNY
Quick Ratio
1.968.432.26
Current Ratio
2.098.552.48
Interest Coverage
−1.85—3.22
Quick Ratio
BBIO
BNTX
ALNY

Profitability

Metric
BBIO
BNTX
ALNY
Return on Assets (Normalized)
−34.80%−3.31%50.54%
Return on Equity (Normalized)
—−3.78%204.12%
Return on Invested Capital (Normalized)
−212.37%−4.37%112.35%
Return on Assets
BBIO
BNTX
ALNY

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|lsM@yXNLOCK|C#Wfl$137B
Regeneron Pharmaceuticals Inc
REGN
LOCK|%tZDLK!LOCK|r<SSq$99B
Moderna Inc
MRNA
LOCK|>$>w?T@LOCK|xz#$90B
argenx SE ADR
ARGX
LOCK|%m?qV^KLOCK|@<#$61B
BeOne Medicines Ltd ADR
ONC
LOCK|Db#&ZZVLOCK|qk$48B
Royalty Pharma PLC Class A
RPRX
LOCK|TSF<$%q$LOCK|#P%Lc$31B
Incyte Corp
INCY
LOCK|<y<!&!LOCK|J>$25B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|t?LL%^vLOCK|?g&N$22B
BioNTech SE ADR
BNTX
LOCK|n#rLnpTLOCK|PG$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|Fymx?>LOCK|>^f$16B

Sponsor Center